Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Procoagulant imbalance in premenopausal women with chronic migraine.

Ferroni P, Barbanti P, Aurilia C, Egeo G, Fofi L, La Farina F, Valente MG, De Marchis ML, Spila A, Palmirotta R, Della-Morte D, Guadagni F.

Neurology. 2017 Oct 3;89(14):1525-1527. doi: 10.1212/WNL.0000000000004435. Epub 2017 Aug 25. No abstract available.

PMID:
28842452
2.

Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer.

Guadagni F, Riondino S, Formica V, Del Monte G, Morelli AM, Lucchetti J, Spila A, D'Alessandro R, Della-Morte D, Ferroni P, Roselli M.

World J Gastroenterol. 2017 Jul 28;23(28):5187-5195. doi: 10.3748/wjg.v23.i28.5187.

3.

Prognostic value of glycated hemoglobin in colorectal cancer.

Ferroni P, Formica V, Della-Morte D, Lucchetti J, Spila A, D'Alessandro R, Riondino S, Guadagni F, Roselli M.

World J Gastroenterol. 2016 Dec 7;22(45):9984-9993. doi: 10.3748/wjg.v22.i45.9984.

4.

Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle.

Riondino S, Ferroni P, Spila A, Alessandroni J, D'Alessandro R, Formica V, Della-Morte D, Palmirotta R, Nanni U, Roselli M, Guadagni F.

Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):291-9. Review.

PMID:
26543078
5.

Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.

Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, Guadagni F.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju054. doi: 10.1093/jnci/dju054.

6.

Association between migraine and ACE gene (insertion/deletion) polymorphism: the BioBIM study.

Palmirotta R, Barbanti P, Ludovici G, De Marchis ML, Ialongo C, Egeo G, Aurilia C, Fofi L, Abete P, Spila A, Ferroni P, Della-Morte D, Guadagni F.

Pharmacogenomics. 2014 Feb;15(2):147-55. doi: 10.2217/pgs.13.186.

PMID:
24444405
7.

Effects of conventional therapeutic interventions on the number and function of regulatory T cells.

Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F.

Oncoimmunology. 2013 Oct 1;2(10):e27025.

8.

A reliable and reproducible technique for DNA fingerprinting in biorepositories: a pilot study from BioBIM.

Palmirotta R, De Marchis ML, Ludovici G, Ialongo C, Leone B, Lopez N, Valente MG, Spila A, Ferroni P, Della-Morte D, Guadagni F.

Int J Biol Markers. 2013 Dec 17;28(4):e398-404. doi: 10.5301/JBM.5000044.

PMID:
23873620
9.

Establishment of a biorepository for migraine research: the experience of Interinstitutional Multidisciplinary BioBank (BioBIM).

Palmirotta R, Barbanti P, Ludovici G, Egeo G, Aurilia C, Fofi L, De Marchis ML, Spila A, Ferroni P, Della-Morte D, Guadagni F.

Neurol Sci. 2013 Sep;34(9):1659-63. doi: 10.1007/s10072-013-1308-x. Epub 2013 Jan 26.

PMID:
23354611
10.

SPRECware: software tools for Standard PREanalytical Code (SPREC) labeling - effective exchange and search of stored biospecimens.

Nanni U, Betsou F, Riondino S, Rossetti L, Spila A, Valente MG, Della-Morte D, Palmirotta R, Roselli M, Ferroni P, Guadagni F.

Int J Biol Markers. 2012 Oct 8;27(3):e272-9. doi: 10.5301/JBM.2012.9718.

PMID:
23032579
11.

Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.

Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton D, Huang B, Tucker J, Tsang KY, Schlom J, Palena C.

Clin Cancer Res. 2012 Jul 15;18(14):3868-79. doi: 10.1158/1078-0432.CCR-11-3211. Epub 2012 May 18.

12.

Impact of preanalytical handling and timing for peripheral blood mononuclear cells isolation and RNA studies: the experience of the Interinstitutional Multidisciplinary BioBank (BioBIM).

Palmirotta R, De Marchis ML, Ludovici G, Leone B, Savonarola A, Ialongo C, Spila A, De Angelis F, Ferroni P, Della-Morte D, Guadagni F.

Int J Biol Markers. 2012 Jul 19;27(2):e90-8. doi: 10.5301/JBM.2012.9235.

PMID:
22562396
13.

An AT-rich region in the APC gene may cause misinterpretation of familial adenomatous polyposis molecular screening.

Palmirotta R, De Marchis ML, Ludovici G, Leone B, Valente MG, Alessandroni J, Spila A, Della-Morte D, Guadagni F.

Hum Mutat. 2012 May;33(5):895-8. doi: 10.1002/humu.22043. Epub 2012 Mar 22.

PMID:
22447671
14.

RFID as a new ICT tool to monitor specimen life cycle and quality control in a biobank.

Nanni U, Spila A, Riondino S, Valente MG, Somma P, Iacoboni M, Alessandroni J, Papa V, Della-Morte D, Palmirotta R, Ferroni P, Roselli M, Guadagni F.

Int J Biol Markers. 2011 Apr-Jun;26(2):129-35. doi: 10.5301/JBM.2011.8323.

PMID:
21574153
15.

Preanalytical Procedures for DNA Studies: The Experience of the Interinstitutional Multidisciplinary BioBank (BioBIM).

Palmirotta R, Ludovici G, De Marchis ML, Savonarola A, Leone B, Spila A, De Angelis F, Della Morte D, Ferroni P, Guadagni F.

Biopreserv Biobank. 2011 Mar;9(1):35-45. doi: 10.1089/bio.2010.0027.

PMID:
24850204
16.

Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer.

Ferroni P, Spila A, D'Alessandro R, Martini F, Iacovone F, Ettorre GM, Vennarecci G, Santoro R, Puoti C, Guadagni F.

Clin Chim Acta. 2011 Feb 20;412(5-6):450-4. doi: 10.1016/j.cca.2010.11.026. Epub 2010 Nov 25.

PMID:
21111726
17.

Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients.

Ferroni P, Roselli M, Spila A, D'Alessandro R, Portarena I, Mariotti S, Palmirotta R, Buonomo O, Petrella G, Guadagni F.

Cancer. 2010 Jun 15;116(12):2913-21. doi: 10.1002/cncr.25094.

18.

Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions.

Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P.

Clin Biochem. 2010 May;43(7-8):666-70. doi: 10.1016/j.clinbiochem.2009.12.021. Epub 2010 Jan 11.

PMID:
20060822
19.

Determinants of homocysteine levels in colorectal and breast cancer patients.

Ferroni P, Palmirotta R, Martini F, Riondino S, Savonarola A, Spila A, Ciatti F, Sini V, Mariotti S, Del Monte G, Roselli M, Guadagni F.

Anticancer Res. 2009 Oct;29(10):4131-8.

20.

Prognostic significance of serum adipokine levels in colorectal cancer patients.

Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P.

Anticancer Res. 2009 Aug;29(8):3321-7.

21.

Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma.

Mattioni M, Soddu S, Porrello A, D'Alessandro R, Spila A, Guadagni F.

Int J Biol Markers. 2007 Oct-Dec;22(4):302-6.

PMID:
18161662
22.

Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer.

Ferroni P, Palmirotta R, Spila A, Martini F, Formica V, Portarena I, Del Monte G, Buonomo O, Roselli M, Guadagni F.

Oncology. 2006;71(3-4):176-84. Epub 2007 Jul 23.

PMID:
17652942
23.

Prognostic significance of adiponectin levels in non-metastatic colorectal cancer.

Ferroni P, Palmirotta R, Spila A, Martini F, Raparelli V, Fossile E, Mariotti S, Del Monte G, Buonomo O, Roselli M, Guadagni F.

Anticancer Res. 2007 Jan-Feb;27(1B):483-9.

24.

Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer.

Ferroni P, Spila A, Martini F, D'Alessandro R, Mariotti S, Del Monte G, Graziano P, Buonomo O, Guadagni F, Roselli M.

Oncology. 2005;69(2):145-53. Epub 2005 Aug 24.

PMID:
16127285
25.

Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients.

Martini F, Ferroni P, Guadagni F, Basili S, Spila A, D'Alessandro R, Mineo D, Laudisi A, Portarena I, Mariotti S, Ambrogi V, Mineo TC, Roselli M.

Anticancer Res. 2005 Jan-Feb;25(1B):403-7.

26.

Prognostic value of soluble P-selectin levels in colorectal cancer.

Ferroni P, Roselli M, Martini F, D'Alessandro R, Mariotti S, Basili S, Spila A, Aloe S, Palmirotta R, Maggini A, Del Monte G, Mancini R, Graziano F, Cosimelli M, Guadagni F.

Int J Cancer. 2004 Sep 1;111(3):404-8.

27.

Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients.

Guadagni F, Ferroni P, Basili S, Facciolo F, Carlini S, Crecco M, Martini F, Spila A, D'Alessandro R, Aloe S, Cerasoli V, Del Monte G, Mariotti S, Mineo TC, Roselli M.

Lung Cancer. 2004 Jun;44(3):303-10.

PMID:
15140543
28.

Soluble CD40 ligand plasma levels in lung cancer.

Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, Del Monte G, Ambrogi V, Spila A, Palmirotta R, D'Alessandro R, Davì G, Guadagni F, Ferroni P.

Clin Cancer Res. 2004 Jan 15;10(2):610-4.

29.

Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer.

Roselli M, Guadagni F, Martini F, Spila A, Mariotti S, D'Alessandro R, Aloe S, Gazzaniga PP, Basili S, Cosimelli M, Ferroni P.

Oncology. 2003;65(2):132-8.

PMID:
12931019
30.

Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases.

Mancini R, Tedesco M, Garufi C, Filippini A, Arcieri S, Caterino M, Pizzi G, Cortesi E, Spila A, Sperduti I, Cosimelli M.

Anticancer Res. 2003 Mar-Apr;23(2C):1837-41.

PMID:
12820466
31.

Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer.

Aloe S, D'Alessandro R, Spila A, Ferroni P, Basili S, Palmirotta R, Carlini M, Graziano F, Mancini R, Mariotti S, Cosimelli M, Roselli M, Guadagni F.

Int J Biol Markers. 2003 Jan-Mar;18(1):21-7.

PMID:
12699059
32.

Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers.

Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A, Ambrogi V, Spila A, D'Alessandro R, Gazzaniga PP, Guadagni F, Ferroni P.

Thromb Haemost. 2003 Jan;89(1):177-84.

PMID:
12540968
33.

Minimal sentinel node procedure for staging early breast cancer.

Mariotti S, Buonomo O, Guadagni F, Spila A, Schiaroli S, Cipriani C, Simonetti G, Felici A, Granal AV, Bellotti A, Cabassi A, Casciani CU, Roselli M.

Tumori. 2002 May-Jun;88(3):S45-7.

PMID:
12365388
34.

Soluble selectin levels in patients with lung cancer.

Roselli M, Mineo TC, Martini F, Mariotti S, Ambrogi V, Spila A, D'Alessandro R, Basili S, Guadagni F, Ferroni P.

Int J Biol Markers. 2002 Jan-Mar;17(1):56-62.

PMID:
11936588
35.

Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.

D'Alessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, Carone MD, Abbolito MR, Carlini S, Perri P, Ricciotti A, Botti C, Conti F, Vici P, Chiappetta NR, Cognetti F, Buonomo O, Guadagni F.

Breast Cancer Res Treat. 2001 Jul;68(1):9-19.

PMID:
11678313
36.

Effects of isolated limb perfusion with tumor necrosis factor-alpha on circulating levels of proinflammatory cytokines.

Ferroni P, Di Filippo F, Martini F, Spila A, D'Alessandro T, Cavaliere F, Anzà M, Garinei R, Aloe S, Carone MD, Gazzaniga PP, Guadagni F.

J Immunother. 2001 Jul-Aug;24(4):354-62.

PMID:
11565837
37.

A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.

Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D'Alessandro R, Carone MD, Cicchetti A, Ricciotti A, Venturo I, Perri P, Di Filippo F, Cognetti F, Botti C, Roselli M.

Clin Cancer Res. 2001 Aug;7(8):2357-62.

38.

Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.

Spila A, Ferroni P, Cosimelli M, D'Alessandro R, Abbolito MR, Mariotti S, Aloe S, Carone MD, Graziano F, Tedesco M, Martini F, Mancini R, Stigliano V, Roselli M, Guadagni F.

Anticancer Res. 2001 Mar-Apr;21(2B):1263-70.

PMID:
11396197
39.

Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.

Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J.

Cancer Res. 2001 Mar 15;61(6):2523-32.

40.

Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer.

Spila A, Ferroni P, Cosimelli M, D'Alessandro R, Carone MD, Aloe S, Tedesco M, Mancini R, Casale V, Carlini S, Casciani CU, Roselli M, Guadagni F.

Anticancer Res. 1999 Mar-Apr;19(2B):1363-8.

PMID:
10365107
41.

Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation.

Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, D'Alessandro R, Fracasso PL, Casale V, Vecchione A, Casciani CU, Greiner JW, Schlom J.

Int J Cancer. 1997 Sep 17;72(6):949-54.

42.

Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay.

Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito MR, Casale V, Pericoli MN, Vecchione A, Casciani CU, Greiner JW, Schlom J.

Cancer Res. 1996 Nov 15;56(22):5293-8.

43.

Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients.

Spila A, Roselli M, Cosimelli M, Ferroni P, Cavaliere F, Arcuri R, Tedesco M, Carlini S, D'Alessandro R, Perri P, Casciani CU, Greiner JW, Schlom J, Guadagni F.

Anticancer Res. 1996 Jul-Aug;16(4B):2241-7.

PMID:
8694550
44.

TAG-72 expression and its role in the biological evaluation of human colorectal cancer.

Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Arcuri R, Carlini S, Mariotti S, Gandolfo GM, Casciani CU, Greiner JW, Schlom J.

Anticancer Res. 1996 Jul-Aug;16(4B):2141-8. Review.

PMID:
8694534
45.

CA 72-4 serum marker--a new tool in the management of carcinoma patients.

Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW, et al.

Cancer Invest. 1995;13(2):227-38. Review.

PMID:
7874576
46.

Possible involvement of tumour cell membrane gangliosides in platelet-tumour cell interactions.

Ferroni P, Lenti L, Guadagni F, Martini F, D'Agostino F, Spila A, Pontieri GM, Gazzaniga PP.

Eur J Cancer. 1995;31A(1):79-84.

PMID:
7695984
47.

Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases.

Guadagni F, Marth C, Zeimet AG, Ferroni P, Spila A, Abbolito R, Roselli M, Greiner JW, Schlom J.

Am J Obstet Gynecol. 1994 Nov;171(5):1183-91.

PMID:
7977516
48.

Biologic and clinical correlations among ploidy, cell kinetics, and the tumor-associated glycoprotein-72 tissue expression in colorectal cancer. Preliminary findings.

Cavaliere F, Guadagni F, D'Agnano I, Casaldi V, Sciarretta F, Spila A, Cosimelli M.

Dis Colon Rectum. 1994 Feb;37(2 Suppl):S24-9.

PMID:
8313788
49.

Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, Part I.

Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, Abbolito MR, Greiner JW, Schlom J.

Dis Colon Rectum. 1994 Feb;37(2 Suppl):S16-23. Review.

PMID:
8313787
50.

Evaluation of the potential role of class II histocompatibility antigen HLA-DR in platelet/tumor cell interaction.

Ferroni P, Guadagni F, Spila A, Martini F, Gazzaniga PP.

Cancer Res. 1994 Feb 1;54(3):623-5.

Supplemental Content

Support Center